In contrast, the suppression of SCD in MITFlow melanoma cells accentuates the invasive and metastatic capacity by activating inflammation-related signaling and induces de-differentiation state.91 In addition to the above-mentioned biological effects, MITF expression can also dictate the sensitivity of BRAF-mutant melanoma to MAPK- inhibition-targeted therapy, though the role is paradoxical in terms of the phase of drug resistance establishment. The gene discussed is BRAF; the disease is melanoma.